Intel stock extends gains after report of possible U.S. government stake
Genmab (CSE:GMAB) A/S (NASDAQ:GMAB), a biotechnology company based in Copenhagen, Denmark, announced an update to its share buyback program in a recent SEC filing. The company revealed that transactions related to the buyback occurred from May 26 to May 28, 2025. This information was disclosed in a Form 6-K submitted to the U.S. Securities and Exchange Commission.
The filing indicates that Genmab is continuing its efforts to repurchase shares as part of a previously announced buyback initiative. This move is part of the company’s strategy to manage its capital structure and return value to shareholders. The specific details of the transactions, including the number of shares repurchased and the total expenditure, were not disclosed in the filing.
Genmab, known for its work in pharmaceutical preparations, is actively engaged in the life sciences sector. The company’s decision to execute share buybacks is aligned with common practices in the industry, where companies often repurchase shares to enhance shareholder value and optimize capital allocation.
The filing was signed by Anthony Pagano, Executive Vice President and Chief Financial Officer of Genmab. The company continues to file annual reports under Form 20-F, as indicated in the document.
This report is based on a press release statement submitted to the SEC.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.